IL114140A - Anti-metastatic and anti-angiogenetic pharmaceutical compositions - Google Patents

Anti-metastatic and anti-angiogenetic pharmaceutical compositions

Info

Publication number
IL114140A
IL114140A IL11414095A IL11414095A IL114140A IL 114140 A IL114140 A IL 114140A IL 11414095 A IL11414095 A IL 11414095A IL 11414095 A IL11414095 A IL 11414095A IL 114140 A IL114140 A IL 114140A
Authority
IL
Israel
Prior art keywords
angiogenetic
metastatic
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL11414095A
Other languages
English (en)
Other versions
IL114140A0 (en
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Priority to IL11414095A priority Critical patent/IL114140A/xx
Publication of IL114140A0 publication Critical patent/IL114140A0/xx
Priority to CA002224560A priority patent/CA2224560A1/en
Priority to US08/981,088 priority patent/US6146824A/en
Priority to AU60146/96A priority patent/AU6014696A/en
Priority to PCT/IL1996/000012 priority patent/WO1997000077A1/en
Priority to EP96917642A priority patent/EP0837689A4/de
Publication of IL114140A publication Critical patent/IL114140A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL11414095A 1995-06-14 1995-06-14 Anti-metastatic and anti-angiogenetic pharmaceutical compositions IL114140A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL11414095A IL114140A (en) 1995-06-14 1995-06-14 Anti-metastatic and anti-angiogenetic pharmaceutical compositions
CA002224560A CA2224560A1 (en) 1995-06-14 1996-06-12 Anti-metastatic and anti-angiogenic pharmaceutical compositions
US08/981,088 US6146824A (en) 1995-06-14 1996-06-12 Method for determining tumor cell adhesion
AU60146/96A AU6014696A (en) 1995-06-14 1996-06-12 Anti-metastatic and anti-angiogenic pharmaceutical compositions
PCT/IL1996/000012 WO1997000077A1 (en) 1995-06-14 1996-06-12 Anti-metastatic and anti-angiogenic pharmaceutical compositions
EP96917642A EP0837689A4 (de) 1995-06-14 1996-06-12 Pharmazeutische zusammensetzungen zur hemmung von metastaten und der angiogenese

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11414095A IL114140A (en) 1995-06-14 1995-06-14 Anti-metastatic and anti-angiogenetic pharmaceutical compositions

Publications (2)

Publication Number Publication Date
IL114140A0 IL114140A0 (en) 1995-10-31
IL114140A true IL114140A (en) 2000-06-01

Family

ID=11067608

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11414095A IL114140A (en) 1995-06-14 1995-06-14 Anti-metastatic and anti-angiogenetic pharmaceutical compositions

Country Status (6)

Country Link
US (1) US6146824A (de)
EP (1) EP0837689A4 (de)
AU (1) AU6014696A (de)
CA (1) CA2224560A1 (de)
IL (1) IL114140A (de)
WO (1) WO1997000077A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886151A (en) * 1996-05-03 1999-03-23 Regents Of The University Of Minnesota Candida albicans integrin-like protein
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
US7785810B2 (en) * 2000-09-09 2010-08-31 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
WO2004085473A2 (en) * 2003-03-28 2004-10-07 Fuji Photo Film B.V. Rgd-enriched gelatine-like proteins with enhanced cell binding
US12076415B2 (en) 2017-08-18 2024-09-03 King Fahd University Of Petroleum And Minerals Use of nano-sized clay crystallites to restore adhesion among tumor and aging stem cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5049659A (en) * 1988-02-09 1991-09-17 Dana Farber Cancer Institute Proteins which induce immunological effector cell activation and chemattraction

Also Published As

Publication number Publication date
EP0837689A4 (de) 2001-05-23
IL114140A0 (en) 1995-10-31
WO1997000077A1 (en) 1997-01-03
AU6014696A (en) 1997-01-15
US6146824A (en) 2000-11-14
EP0837689A1 (de) 1998-04-29
CA2224560A1 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL116917A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
HUP0002209A3 (en) 4-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives and pharmaceutical compositions containing them
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
HUP9900424A2 (hu) Tiazolil-benzfurán-származékok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
ZA967827B (en) Pharmaceutical compositions
HUP9802290A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
HUP9602196A2 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
IL117623A0 (en) Maltitol compositions and its preparation
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
GB9513972D0 (en) Pharmaceutical compositions
ZA963397B (en) Esters and pharmaceutical compositions
HUP9802291A3 (en) Penicillaminamide derivatives and pharmaceutical compositions containing them
IL114140A0 (en) Anti-metastatic and anti-angiogenetic pharmaceutical
HUP9602223A3 (en) Biotin derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees